Mucocutaneous manifestations among persons receiving highly active anti-retroviral therapy
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20170800Keywords:
Mucocutaneous manifestations, Opportunistic infection, HIV, HAART, CD4 countAbstract
Background: Mucocutaneous manifestations in patients positive for HIV are helpful in the diagnosis as well as treatment of the disease. Consequent to the introduction of Highly Active Anti-Retroviral Therapy (HAART), there seems to be an increase in the presentation of non-infective diseases. It was aimed to analyse the mucocutaneous manifestations in HIV infected patients taking HAART and correlate with age and CD4 lymphocyte count.
Methods: A retrospective analysis of 125 People Living With HIV (PLWH) having mucocutaneous manifestations receiving HAART who attended a tertiary care city hospital over a period of ten months from January 2016 to October 2016 was carried out. The findings were correlated with CD4 count and age. The data were collected from the patient follow up cards maintained by qualified Dermatovenereologist.
Results: There was no major gender difference in our study. The trans genders presented with only non-infectious skin diseases. Younger patients had a higher CD4 count (p=0.01%) which was statistically significant. Candidiasis and pruritic papular eruption were the commonest infective and non-infective diseases observed respectively. The mean CD4 count comparison was statistically significant (p=0.04). The count was highest for insect bite allergy and lowest for oral hairy leukoplakia. The mean age of disease manifestation was highest for Herpes zoster and lowest for aphthous ulcers 45 and 29 years respectively. All the adverse reactions observed were to efavirenz.
Conclusions: With the improvement of CD4 count in PLWH receiving HAART, the proportion of non-infectious inflammatory disease manifestations are on the rise. Awareness about this fact is very important for effective management.
Metrics
References
Laurance J. "Suniti Solomon". The Lancet. 2015;386:1818.
Sud N, Shanker V, Sharma, A, Sharma NL, Gupta M. Mucocutaneous manifestations in 150 HIV-infected Indian patients and their relationship with CD4 lymphocyte counts. Int J STD AIDS 2009;20:771–4.
Sivayathorn A, Srihra B, Leesanguankul W. Prevalence of skin disease in patients infected human immunodeficiency virus in Bangkok, Thailand. Ann Acad Med Singapore. 1995;24:528–33.
Wiwanitkit V. Prevalence of dermatological disorders in Thai HIV-infected patients correlated with different CD4 lymphocyte count statuses: a note on 120 cases. Int J Dermatol. 2004;43:265–8.
Foroughi M, Koochak HE, Roosta N, Paydary K, Khatami A, Shahriari S, et al. Prevalence of dermatologic manifestations among people living with HIV/ AIDS in Imam Khomeini Hospital in Tehran, Iran. J AIDS HIV Res. 2012;4:56–9.
HIV Classification: CDC and WHO Staging Systems. Available at https://www.aidsetc.org/guide/hiv-classification-cdc-and-who-staging-systems. Accessed 20 November 2016.
Cedeno-Laurent F, Gomez-Flores M, Mendez N, Ancer-Rodriquez J, Bryant JL, Gaspari AA, Trujillo JR. New insights into HIV-1-primary skin disorders. J Int AIDS Soc. 2011;14:5.
Azfar NA, Khan AR, Zia MA, Humayun A, Malik LM, Jahangir M. Frequency of mucocutaneous manifestations in HIV positive Pakistani patients. J Pak Assoc Dermatol. 2011;21:149–53.
Spira R, Mingard M, Doutre MS, Molart P, Dabis F. Prevalence of cutaneous disorders in a population of HIV-infected patients. Arch Dermatol. 1998;134:1208–12.
Berger TG, Greene I. Bacterial, viral, fungal, and parasitic infections in HIV disease and AIDS. Dermatol Clin. 1991;14:465–92.
Hood S, Bonington A, Evans J, Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS. 1998;12(4):447–8.
Özlem AA, Hayat KK, Ramazan K, Mehmet O, Özcan N. Mucocutaneous manifestations and the relationship to CD4 lymphocyte counts among Turkish HIV/AIDS patients in İstanbul, Turkey. Turk J Med Sci. 2015;45:89-92.
Cedeno-Laurent F, Gómez-Flores M, Mendez N, Ancer-Rodríguez J, Bryant JL, Gaspari AA, et al. New insights into HIV-1-primary skin disorders. J Int AIDS Soc. 2011;24(14):5.
Resneck JS Jr, Van Beek M, Furmanski L, Oyugi J, LeBoit PE, Katabira E, et al. Etiology of pruritic papular eruption with HIV infection in Uganda. JAMA. 2004;14:2614–21.
Froschl M, Land HG, Landthaler M. Seborrheic dermatitis and atopic eczema in human immunodeficiency virus infection. Semin Dermatol. 1990;14:230–2.
Ackerman AB. Histopathologic differentiation of eczematous dermatitides from psoriasis and seborrheic dermatitis. Cutis. 1977;14:619–23.
Eisenstat BA, Wormser GP. Seborrheic dermatitis and butterfly rash in AIDS. N Engl J Med. 1984;14:189.
Rowe A, Mallon E, Rosenberger P, Barrett M, Walsh J, Bunker CB. Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. J Invest Dermatol. 1999;14: 284–9.
Singh F, Rudikoff D. HIV-associated pruritus: etiology and management. Am J Clin Dermatol. 2003;14:177–88.
Majors MJ, Berger TG, Blauvelt A, Smith KJ, Turner ML, Cruz PD Jr. HIV-related eosinophilic folliculitis: a panel discussion. Semin Cutan Med Surg. 1997;14:219–23.
Todd G. Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. Dermatol Clin. 2006;14:459–72.
Punyaratabandhu P, Prasithsirikul W, Jirachanakul J. Skin Manifestation of Thai HIV Infected Patients in HAART Era. J Med Assoc Thai. 2012;95(4):497-504.
Phillips EJ, Kuriakose B, Knowles SR. Efavirenz-induced skin eruption and successful desensitization. Ann Pharmacother. 2002;36(3):430-2.
Khammissa RA, Fourie J, Chandran R, Lemmer J, Feller L. Epstein-Barr Virus and Its Association with Oral Hairy Leukoplakia: A Short Review. Int J Dent. 2016;4941783.
Sontakke SA, Umarji HR, Karjodkar F. Comparison of oral manifestations with CD4 count in HIV-infected patients. Indian J Dent Res. 2011;22:732.
Downloads
Published
How to Cite
Issue
Section
